CancerPACTtm. Cancer Patients Alliance for Clinical Trials. Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011

Transcription

1 CancerPACTtm Cancer Patients Alliance for Clinical Trials Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011 Solid Tumors 1. Breast Central Nervous System Gastrointestinal Gynecologic Head and Neck Lung Melanoma Prostate Urologic Hematologic Cancers 1. Leukemia Lymphoma Myeloma Phase I Studies Other Contact Organizations: Angeles Clinic and Research (ACRI), Associates in Hematology-Oncology (AHC), American Institute of Research (AIR), Breastlink Medical Group (BMG), Center for Breast Care (CBC), Beverly Hills Cancer Center (BH), California Cancer Consortium (CCC), City of Hope (COH), Samuel Oschin, Tower Urology (CS), East Oncology and Hematology (EOH), Glendale Adventist Medical Corp. (GAMC), Greater LA Oncology (GLAO), Glendale Memorial Hospital (GMH), Global Oncology (GO), GSK Investigational Site (GSK), Huntington Cancer Center (HCC), Hollywood Presbyterian (HP), ImClone Ivestigational Site (IMC), Kaiser Permanente (KP), Kenmar Research Institute (KRI), Leavey Cancer Center (LCC), NewLink Genetics (NLG), James Berenson, Oncotherapeutics (OT), Pfizer (PFIZER), Providence Holy Cross (PHC), North Valley Hematology-Oncology, Providence Health & Services (PHS), Premiere Oncology (PO), Prostate Oncology Specialists (POS), Scripps Cancer Center Clinical Research (SCCCR), John Wayne Cancer Institute, Roy and Patricia Disney Family Cancer Center (SJMC), Santa Monica Hematology Oncology (SMHO), Santa Monica Sarcoma Center (SMSC), Southwest Oncology Group (SWOG), Tower Cancer Research Foundation (TCRF), Translational Oncology Research International TORI), Jonsson Cancer Center, Olive View, Pasadena Oncology, UCLA Medical Center, The Regents of UCLA (UCLA), Norris Comprehensive Cancer Center, USC Medical Center, Anthony El-Khoueiry, Westside Prostate Cancer Center (USC), Veterans Affairs Medical Center(VAMC)

2 2 Solid Tumors 1. Breast Cancer 1. NCT Phase III Study of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients with Breast Cancer (USC) 2. NCT Phase III Study of Letrozole with or without Lapatinib in Treating Postmenopausal Women with Stage IV Breast Cancer (KRI, PHS, UCLA) 3. NCT Phase III Breast Cancer Trial of an Investigational Drug vs. Capecitabine in Male or Female Patients with Advanced Breast Cancer 4. NCT Phase III Randomized Study of Radiation Therapy in Treating Women who have Undergone Surgery for Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer (GAMC, UCLA) 5. NCT Phase III Randomized Study of Hormone Therapy with or without Combination Chemotherapy in Treating Women who have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (PHC, SJMC) 6. NCT Phase III Study of Treatment Decision Making Based on Blood Levels of Tumor Cells in Women with Metastatic Breast Cancer Receiving Chemotherapy (GMH, USC) 7. NCT Phase III Randomized Study of Tamoxifen or Letrozole with or without Bevacizumab in Treating Women with Stage III or Stage IV Breast Cancer (SJMC, USC) 8. NCT Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer (IMC) 9. NCT Phase III Study using Radiation Therapy with or without Trastuzumab in Treating Women with Ductal Carcinoma In Situ who have Undergone Lumpectomy (CS, GMH, PHC, SJMC, UCLA) 10. NCT Phase III Study of Paclitaxel and Trastuzumab with or without Lapatinib in Treating Patients with Stage II or Stage III Breast Cancer that can be Removed by Surgery (SJMC) 11. NCT Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone (The ixabepilone arm has been closed as of 8/15/11)with or without Bevacizumab in Treating Patients with Stage IIIC or Stage IV Breast Cancer (KP, SJMC) 12. NCT Phase III Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer 13. NCT Phase III Trial using Everolimus in Combination with Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (CHO, GLAO, LCC, UCLA) 14. NCT Phase III Study Evaluating the Effects of Neratinib after Adjuvant Trastuzumab in Women with Early Stage Breast Cancer (PFIZER) 15. NCT Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (PHS) 16. NCT Phase III Trial of Continued HER2 Suppression with Lapatinib Plus Trastuzumab vs. Trastuzumab Alone (GSK) 17. NCT Phase III Prediction Study of Response to Neoadjuvant Chemotherapy in Women with Operable Breast Cancer (USC)

3 18. NCT Phase III Study of Daily Everolimus in Combination with Trastuzumab and Vinorelbine in HER2/Neu Positive Women with Locally Advanced or Metastatic Breast Cancer (SMHO) 19. NCT Phase III Trial of Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer (LCC, SJMC, USC) 20. NCT Phase III Study of Chemotherapy with or without Trastuzumab after Surgery in Treating Women with Invasive Breast Cancer (GMH, SJMC) 21. NCT Phase II Study of Bevacizumab and Combination Chemotherapy in Treating Women with Stage II or Stage III Breast Cancer (UCLA) 22. NCT Phase II Study of Capecitabine and Lapatinib with or without Cixutumumab in Treating Patients with Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer (GMH) 23. NCT Phase II Trial using Cryoablation Therapy in Treating Patients with Invasive Ductal Breast Cancer (CBC, SJMC, USC) 24. NCT Phase II Trial using Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women with Stage I, Stage II, or Stage III Breast Cancer that can be Removed by Surgery (PHS) 25. NCT Phase II Study of Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim with or without Bevacizumab in Treating Women with Inflammatory or Locally Advanced Breast Cancer (SJMC, USC) 26. NCT Phase II Trial using Paclitaxel with or without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients with Breast Cancer that can be Removed by Surgery (SJMC) 27. NCT Phase II Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer (KRI) 28. NCT Phase II I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (UCS) 29. NCT Phase II Study of PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)with BRCA1/2 Mutations (UCLA) 30. NCT Phase II Trial of Radiation Therapy in Treating Women with Locally Recurrent Breast Cancer Previously Treated with Repeat Breast-Preserving Surgery (SJMC) 31. NCT Phase II Trial using Veliparib with or without Carboplatin in Treating Patients with Stage III or Stage IV Breast Cancer (USC) 32. NCT Phase II Study of CDX-011 (CR011-vcMMAE) in Patients with Advanced GPNMB-Expressing Breast Cancer (ACRI, USC) 33. NCT Phase II Study of IMC-18F1 or Ramucirumab DP in Combination with Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients (IMC) 34. NCT Phase II Study of Entinostat and Anastrozole in Treating Postmenopausal Women with Triple-Negative Breast Cancer that can be Removed by Surgery (USC) 35. NCT Phase II Study of Azacitidine and Entinostat in Treating Patients with Advanced Breast Cancer (USC) 36. NCT Phase I/II Study of BEZ235 in Patients with Advanced Solid Malignancies Enriched by Patients with Advanced Breast Cancer (UCLA) 37. NCT Phase I/II Study of Letrozole with or without PD for the First-Line Treatment of Hormone-Receptor Positive Advanced Breast Cancer (PFIZER) 38. NCT Phase I/II Study of Vaccine Therapy in Treating Patients with HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers (GMH, HP) 3

4 4 39. NCT Phase I/II Study of XL147 or XL765 in Combination with Letrozole in Subjects with Breast Cancer 40. NCT Phase I/II Safety, Tolerability, and Efficacy Study in Subjects with Advanced or Metastatic Breast Cancer (AHC, BMG) 41. NCT Phase I Study of Zoledronic Acid Administered Monthly vs. Every Three Months in Multiple Myeloma and Breast Cancer Patients who were Treated with Zoledronic Acid the Prior Year (OT) 42. NCT Phase I Study of Ixabepilone and Vorinostat in Treating Patients with Metastatic Breast Cancer (COH) 2. Central Nervous System Tumors 1. NCT Phase III Study of Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients with Newly Diagnosed Anaplastic Glioma (CS) 2. NCT Phase III Study of the Effect of NovoTTF-100A Together with Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) (USC) 3. NCT Phase II Trial using Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (CS) 4. NCT Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma (CS) 5. NCT Phase II Study of Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients with Recurrent Glioblastoma Multiforme (UCLA) 6. NCT Phase II Trial of Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (UCLA) 7. NCT Phase II Trial using Dendritic Cell Vaccine for Patients with Brain Tumors (UCLA) 8. NCT Phase II Study of the Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) (CS) 9. NCT Phase II Study of MEDI-575 in Subjects with Recurrent Glioblastoma Multiforme 10. NCT Phase II Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) (CS) 11. NCT Phase I/II Study of AQ4N in Combination with Radiotherapy and Temozolomide in Subjects with Newly Diagnosed Glioblastoma Multiforme (UCLA) 12. NCT Phase I/II Study of a Retroviral Replicating Vector Administered to Subjects with Recurrent Malignant Glioma (UCLA) 13. NCT Phase I Study of Surgical Resection with Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients (CS) 14. NCT Phase I Study of Immunotherapy for Patients with Brain Stem Glioma and Glioblastoma (CS) 15. NCT Phase I Study of XL765 in Combination with Temozolomide with and without Radiation in Adults with Malignant Gliomas (UCLA) 16. NCT Phase I Study of Cediranib Maleate and Cilengitide in Treating Patients with Progressive or Recurrent Glioblastoma (UCLA) 17. NCT Phase I Cellular Immunotherapy Study for Brain Cancer (UCLA) 18. NCT Phase I Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects with Recurrent Glioblastoma who are Candidates for Surgical Resection

5 5 A. Colorectal Cancer 3. Gastrointestinal Cancers 1. NCT Phase III Randomized Study of Cetuximab and/or Bevacizumab Combined with Combination Chemotherapy in Treating Patients with Metastatic Colorectal Cancer (GMC, KP, SJMC, USC) 2. NCT Phase III Trial using Laparoscopic-Assisted Resection or Open Resection in Treating Patients with Stage IIA, Stage IIIA, or Stage IIIB Rectal Cancer (KP) 3. NCT Phase III Study of Rosuvastatin in Treating Patients with Stage I or Stage II Colon Cancer that was Removed By Surgery (GMH) 4. NCT Phase III Study of Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery (SJMC, USC) 5. NCT Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Radiation Therapy Followed By Surgery in Treating Patients with Stage II or Stage III Rectal Cancer (USC) 6. NCT Phase II Study of CS-7017 in Combination with FOLFIRI in Subjects with Metastatic Colorectal Cancer who Failed First-Line Therapy (BH) 7. NCT Phase II Study of Azacitidine and Entinostat in Treating Patients with Metastatic Colorectal Cancer (USC) 8. NCT Phase I/II Study of KRN330 Plus Irinotecan in Patients with Metastatic Colorectal Cancer (USC) 9. NCT Phase I/II Study of ARQ 197 in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer 10. NCT Phase I Study of Panobinostat and Fluorouracil Followed by Leucovorin Calcium in Treating Patients with Stage IV Colorectal Cancer who did not Respond to Previous Fluorouracil-Based Chemotherapy (USC) B. Esophageal Cancer 1. NCT Phase III Trial of Paclitaxel, Cisplatin, and Radiation Therapy with or without Cetuximab in Treating Patients with Locally Advanced Esophageal Cancer (SJMC) 2. NCT Radiation Therapy, Paclitaxel, and Carboplatin with or without Trastuzumab in Treating Patients With Esophageal Cancer (USC) 3. NCT Phase III Safety and Efficacy Trial of S-1/ Cisplatin Compared to 5-FU/ Cisplatin in Treatment of Patients with Metastatic Diffuse Gastric and Esophagogastric Junction Cancer Previously Untreated with Chemotherapy 4. NCT Phase II Trial using Combination Chemotherapy with or without GDC-0449 in Treating Patients with Advanced Stomach Cancer or Gastroesophageal Junction Cancer (USC) 5. NCT Phase II Trial using Everolimus in Treating Patients with Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer (PHS, UCLA, TORI) 6. NCT Phase II Trial using Irinotecan Hydrochloride with or without Alvocidib in Treating Patients with Advanced Stomach Cancer or Gastroesophageal Junction Cancer (COH, USC) 7. NCT Phase II Study of Ramucirumab in Patients with Gastric, Esophageal and Gastroesophageal Cancer

6 6 8. NCT Phase I Study of BMS with Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas (USC) C. Gastric Cancer 1. NCT LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (GSK) 2. NCT Phase III Study of Paclitaxel with or without Ramucirumab in Metastatic Gastric Adenocarcinoma (IMC) 3. NCT Phase II Study of Irinotecan and Docetaxel in Patients with Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma (USC) 4. NCT Phase II Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer (USC) 5. NCT Phase II Study Evaluating STA-9090 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) (UCLA) D. Liver Cancer 1. NCT Phase III Study of ThermoDox with Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) (UCLA) 2. NCT Phase III Study of First Line Hepato Cellular Carcinoma (HCC) (EOH) 3. NCT Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC (UCLA) 4. NCT Phase III Randomized Study of Chemoembolization with or without Sorafenib Tosylate in Treating Patients with Liver Cancer that cannot be Removed by Surgery (USC) 5. NCT Phase III Efficacy and Tolerability of ABT-869 vs. Sorafenib in Advanced Hepatocellular Carcinoma (HCC) 6. NCT Phase II Study of Intra-Arterial Chemotherapy with Cisplatin and Mitomycin-C in Patients with Hepatocellular Carcinoma (USC) 7. NCT Phase II Study of Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients with Advanced Liver Cancer (USC) 8. NCT Phase II Study of IMC-A12 in Combination with Sorafenib in Patients with Advanced Cancer of the Liver (IMC) 9. NCT Phase II Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) who have Failed One Prior Systemic Therapy 10. NCT Phase II Study of CS1008- in Combination with Sorafenib Compared to Sorafenib alone in Subjects with Advanced Liver Cancer (KRI) 11. NCT Phase II Study of MK2206 in Treating Patients with Advanced Liver Cancer that did not Respond to Previous Therapy (COH, TCRF) 12. OSU Phase II Study of MK2206 in Treating Patients with Advanced Refractory Biliary Cancer that cannot be Removed by Surgery (CCC) 13. NCT Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) (USC)

7 7 14. NCT Phase I Study of Cixutumumab and Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer (COH, USC) E. Pancreatic Cancer 1. NCT Phase III Trial of Patients with Metastatic Adenocarcinoma of the Pancreas (TCRF) 2. NCT Phase III Trial of Gemcitabine Hydrochloride with or without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen with or without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients with Pancreatic Cancer that has been Removed by Surgery (USC) 3. NCT Phase III Immunotherapy Study for Surgically Resected Pancreatic Cancer (NLG) 4. NCT Phase II Study of Gemcitabine Hydrochloride with or without GDC-0449 in Treating Patients with Recurrent or Metastatic Pancreatic Cancer (COH, USC, TCRF) 5. NCT Phase II Study Comparing CO-1.01 with Gemcitabine as First Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma (LEAP) (CCI) 6. NCT Phase II Study of Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients with Pancreatic Cancer Previously Treated with Surgery (PHS, TORI, UCLA) 7. NCT Phase II Trial of Gemcitabine with or without Bavituximab in Patients with Previously Untreated Stage IV Pancreatic Cancer (GO) 8. NCT Phase I Study of RO Before Surgery in Treating Patients with Pancreatic Cancer (COH, TCRF, USC) 4. Gynecologic Cancers A. Ovarian / Peritoneal Cancer 1. NCT Phase III Study of Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients with Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer (CS,KP, SJMC) 2. NCT Phase III Study of Carboplatin and Paclitaxel with or without Bevacizumab after Surgery in Treating Patients with Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (KP) 3. NCT Phase III Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (USC) 4. NCT Phase III Efficacy and Safety Study of MORAb-003 in Subjects with Platinum- Sensitive Ovarian Cancer in First Relapse (UCLA) 5. NCT Phase III Study of Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients with Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (KP, SJMC, UCLA) 6. NCT Phase III Study of Paclitaxel and Carboplatin or Ifosfamide in Treating Patients with Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer (SJMC, UCLA, USC)

8 7. NCT Phase III Study of Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, with or without Bevacizumab, as First-Line Therapy in Treating Patients with Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube (UCLA) 8. NCT Phase III Study of Paclitaxel and Carboplatin with or without Bevacizumab in Treating Patients with Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (CS, SJMC, UCLA) 9. NCT Phase III Study for Women with Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination with Doxil (PROCEED) (KP, SJMC) 10. NCT Phase II Study of Adding AMG 479 to First Line Chemotherapy in Patients with Optimally Debulked Epithelial Ovarian Cancer (UCLA) 11. NCT Phase II Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients with Metastatic or Locally Advanced Ovarian Cancer (USC) 12. NCT Phase II Trial using Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients with Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors (SJMC, UCLA) 13. NCT Phase II Study of Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients with Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer (SJMC) 8 B. Uterine /Cervical Cancer 1. NCT Phase III Study of Paclitaxel and Cisplatin or Topotecan with or without Bevacizumab in Treating Patients with Stage IVB, Recurrent, or Persistent Cervical Cancer (CS, SJMC, UCLA) 2. NCT Phase III Trial of Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients with High-Risk Stage I or Stage II Endometrial Cancer (CS, SJMC) 3. NCT Phase III Study of Carboplatin and Paclitaxel with or without Cisplatin and Radiation Therapy in Treating Patients with Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer (SJMC, UCLA) 4. NCT Phase III Study of Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy (SJMC) 5. NCT Phase III Study of Gemcitabine Hydrochloride and Docetaxel with or without Bevacizumab in Treating Patients with Advanced or Recurrent Uterine Leiomyosarcoma (KP, SJMC, UCLA, USC) 6. NCT Phase III Study of Radiation Therapy with or without Chemotherapy in Patients with Stage I or Stage II Cervical Cancer who Previously Underwent Surgery (SJMC, UCLA) 7. NCT Phase II Trial using Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer (SJMC, UCLA) 8. NCT Phase II Study of Megestrol in Treating Patients with Endometrial Neoplasia or Endometrial Hyperplasia (UCLA) 9. NCT Phase II Study of Second Curettage in Treating Patients with Persistent Non- Metastatic Gestational Trophoblastic Tumor (UCLA) 10. NCT Phase II Study of Pemetrexed and Cisplatin in Treating Patients with Advanced, Persistent, or Recurrent Cervical Cancer (USC)

9 11. NCT Phase II Study of Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients with Stage III, Stage IV, or Recurrent Endometrial Cancer (SJMC, UCLA) 12. NCT Phase II Trial using Temsirolimus in Treating Patients with Recurrent or Persistent Cancer of the Uterus (COH, TCRF) 13. NCT Phase II Study of Brivanib in Treating Patients with Persistent or Recurrent Cervical Cancer (SJMC) 9 5. Head & Neck Cancer 1. NCT Phase III Efficacy Study of Reolysin in Combination with Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers (PHS) 2. NCT Phase II Study of Temozolomide in Treating Patients with Invasive Pituitary Tumors (UCLA) 3. NCT Phase II Study of Rosiglitazone in Treating Patients with Newly Diagnosed ACTH- Secreting Pituitary Tumor (Cushing Disease) (UCLA) 4. NCT Phase II Targeted Therapy with Lapatinib in Patients with Recurrent Pituitary Tumors Resistant to Standard Therapy (CS) 5. NCT Phase II Study in Head and Neck Cancer 6. NCT Phase II Trial of Capecitabine and Vorinostat in Treating Patients with Recurrent and/or Metastatic Head and Neck Cancer (COH, TCRF, USC) 6. Lung 1. NCT Phase III Trial using Chemotherapy with or without Bevacizumab in Treating Patients with Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer that was Removed by Surgery (GMH, SJMC, USC) 2. NCT Phase III Cancer Vaccine Study for Unresectable Stage III Non-Small Cell Lung Cancer (CS, GAMC, USC) 3. NCT Phase III Trial using GSK A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Non-Small Cell Lung Cancer (GSK) 4. NCT Phase III Comparison of Different Types of Surgery in Treating Patients with Stage IA Non-Small Cell Lung Cancer (HCC) 5. NCT Phase III Study of Carboplatin with Either Paclitaxel Poliglumex or Paclitaxel in Treating Women with Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (SJMC) 6. NCT Phase III Randomized Study of Three Different Radiation Therapy Regimens in Treating Patients with Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide (SJMC) 7. NCT Phase III Study of Lucanix Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (UCLA) 8. NCT Phase III Trial using Sunitinib as Maintenance Therapy in Treating Patients with Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated with Combination Chemotherapy (KP) 9. NCT Phase III Study of Pemetrexed, Carboplatin and Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer

10 10. NCT Phase III Study of Chemotherapy or Observation in Treating Patients with Early Stage Non-Small Cell Lung Cancer (SJMC) 11. NCT Phase III Trial of the Investigational Drug, PF Being Studied vs. Standard of Care in Patients with Advanced Non-Small Cell Lung Cancer with a Specific Gene Profile Involving the Anaplastic Lymphoma Kinase (ALK) Gene (PFIZER) 12. NCT Phase III Study of Carboplatin and Paclitaxel with or without Bevacizumab and/or Cetuximab in Treating Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer (USC) 13. NCT Phase III Study of Patients with Advanced Non-Small Cell Lung Cancer 14. NCT Phase III Trial of Gemcitabine/Carboplatin with or without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects with Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) 15. NCT Phase III Clinical Trial Testing the Efficacy of Crizotinib vs. Standard Chemotherapy Pemetrexed Plus Cisplatin or Carboplatin in Patients with ALK Positive Non Squamous Cancer of the Lung (PFIZER) 16. NCT Phase III Study in Second Line Non Small Cell Lung Cancer 17. NCT Phase III Trial of ARQ 197 Plus Erlotinib vs. Placebo Plus Erlotinib for the Treatment of Non-Squamous, Non-Small-Cell Lung Cancer 18. NCT Phase III/II Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (PO) 19. NCT Phase II Study of ZD6474, Carboplatin, and Paclitaxel in Treating Patients with Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (UCLA) 20. NCT Phase II Trial of Erlotinib Hydrochloride with or without Celecoxib in Treating Patients with Stage IIIB-IV Non-Small Cell Lung Cancer (COH) 21. NCT Phase II Trial using Erlotinib with or without Carboplatin and Paclitaxel in Treating Patients with Stage IIIB or Stage IV Non-Small Cell Lung Cancer (USC) 22. NCT Phase II Study of Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (KP) 23. NCT Phase II Study of Everolimus in Treating Patients with Pleural Malignant Mesothelioma that cannot be Removed by Surgery (USC) 24. NCT Phase II Study of Efficacy and Safety of Apricoxib/Placebo with Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients (USC) 25. NCT Phase II Trial to Evaluate the Safety and Efficacy of the Investigational Drug PF in Patients with Advanced Non-Small Cell Lung Cancer with a Specific Gene Profile Involving the Anaplastic Lymphoma Kinase (ALK) Gene (PFIZER) 26. NCT Phase II Study of Erlotinib with or without Fulvestrant in Treating Patients with Stage IIIB or Stage IV Non-Small Cell Lung Cancer (UCLA) 27. NCT Phase II Study of the HSP90 Inhibitor, STA-9090 in Subjects with Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) (PO) 28. NCT Phase II Study of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways (UCLA) 29. NCT Phase II Study of LY in Combination with Docetaxel vs. Docetaxel in Patients with Non-Small Cell Lung Cancer 30. NCT Phase II Study of AUY922 in Non-Small-Cell Lung Cancer Patients who have Received Previous Two Lines of Chemotherapy (UCLA) 31. NCT Phase II Safety and Efficacy Study of Farletuzumab in Subjects with Adenocarcinoma of the Lung (GAMC) 10

11 32. NCT Phase II Study of Erlotinib (Tarceva) in Combination with OSI-906 in Patients with Advanced Non-Small Cell Lung Carcinoma (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene (SJMC) 33. NCT Phase II Study of MK2206 and Erlotinib Hydrochloride in Treating Patients with Advanced Non-Small Cell Lung Cancer who have Progressed after Previous Response to Erlotinib Hydrochloride Therapy (COH, TCRF, USC) 34. NCT Phase I/II Study of Azacitidine and MS-275 in Treating Patients with Recurrent Advanced Non-Small Cell Lung Cancer (USC) 35. NCT Phase I/II Trial using Stereotactic Body Radiation Therapy in Treating Patients with Stage I Non-Small Cell Lung Cancer (SJMC) 36. NCT Phase I/II Trial using Maximum Tolerated Dose Study of Belinostat (PXD- 101)in Combination with Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC) (SOC, TCRF) 37. NCT Phase II Study Evaluating the Safety and Efficacy of MEGF0444A in Combination with Carboplatin, Paclitaxel and Bevacizumab in Patients with Advanced or Recurrent Non- Squamous Non-Small Cell Lung Cancer who have not Received Prior Chemotherapy for Advanced Disease 38. NCT Phase I/II Study of Veliparib with or without Radiation Therapy, Carboplatin, and Paclitaxel in Patients with Stage III Non-Small Cell Lung Cancer that cannot be Removed by Surgery (COH, TCRF, USC) 39. NCT Phase I Study of Celecoxib in Treating Patients with Stage IIIB or Stage IV Non- Small Cell Lung Cancer (UCLA) 40. NCT Phase I Study of Vaccine Therapy in Treating Patients with Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (UCLA) 41. NCT Phase I Study of Patients who will Undergo Surgical Removal of Non-Small Cell Lung Cancer to Evaluate Molecular Changes that Occur in Tumor Tissue after Short Term Exposure to PF (PFIZER) Melanoma 1. NCT Phase III Treatment Combination for Patients with Unresectable Stage III or Stage IV Melanoma (ACRI) 2. NCT Phase III Efficacy Study of Ipilimumab vs. Placebo to Prevent Recurrence after Complete Resection of High Risk Stage III Melanoma (ACRI) 3. NCT Phase III Study of Stage IV Surgery vs. Best Medical Therapy in Treatment of Stage IV Melanoma (SJHC) 4. NCT Phase III Study Comparing GSK to Dacarbazine (DTIC) in Previously Untreated Subjects with BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma (GSK) 5. NCT Phase II Study of Imatinib Mesylate in Treating Patients with Stage III or Stage IV Melanoma that cannot be Removed by Surgery (UCLA) 6. NCT Phase II Safety and Efficacy Study of Marqibo in Metastatic Malignant Uveal Melanoma (UCLA) 7. NCT Phase II Study of Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanom (ACRI) 8. NCT Phase II Study of Gene Modified Immune Cells in Patients with Advanced Melanoma (UCLA)

12 9. NCT Phase II Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a C-Kit Mutation (UCLA) 10. NCT Phase II Study of ONTAK in Patients with Stage IIIC and Stage IV Melanoma (ACRI) 11. NCT Phase II Study of RO in Patients with Metastatic Melanoma 12. NCT Phase II Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma (ACRI, UCLA) 13. INCT Phase II Randomized Study of Interleukin-21 (ril-21) vs. Dacarbazine (DTIC) in Patients with Metastatic or Recurrent Melanoma (ACRI) 14. NCT Phase I/II Trial using Combination of Temozolomide and Sunitinib in Treatment of Patients with Metastatic and Unresectable Malignant Melanoma (UCLA) 15. NCT Phase I/II Study of ALT-801 with Cisplatin in Patients with Metastatic Melanoma (ACRI) 16. NCT Phase I Trial of an Intratumoral Injections of INXN-3001 in Subjects with Stage III or IV Melanoma (ACRI) 17. NCT Phase I Dose Escalation Study of MLN4924 in Adults with Melanoma (ACRI) 18. NCT Phase I Study of the Effect of Food on the Pharmacokinetics of Single Dose RO and the Safety And Efficacy of Continuous Administration in Patients with BRAF V600E Mutation-Positive Metastatic Melanoma 19. NCT Phase I Study of RO And GDC-0973 in Patients with BRAF-Mutation Positive Metastatic Melanoma Prostate Cancer 1. NCT Phase III Study of Chemotherapy after Prostatectomy (CAP) for High Risk Prostate Carcinoma (CS) 2. NCT Phase III Study of Androgen Ablation Therapy with or without Chemotherapy in Treating Patients with Metastatic Prostate Cancer (SJMC, USC) 3. NCT Phase III Trial using Surgery with or without Docetaxel and Leuprolide or Goserelin in Treating Patients with High-Risk Localized Prostate Cancer (USC) 4. NCT Phase III Randomized Study of Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy with or without Prostate Radiation Therapy in Treating Patients with a Rising PSA after Surgery for Prostate Cancer (CS) 5. NCT Phase III Study of Immunotherapy to Treat Advanced Prostate Cancer (POS, USC) 6. NCT Phase III Study of Radiation Therapy with or without Androgen-Deprivation Therapy in Treating Patients with Prostate Cancer (SJMC) 7. NCT Phase III Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination with Docetaxel and Prednisone for Patients with Castrate-Resistant Prostate Cancer (USC) 8. NCT Phase III Study of Immunotherapy to Treat Advanced Prostate Cancer (POS) 9. NCT Phase III Study Comparing Orteronel plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer 10. NCT Phase III Study Comparing Orteronel plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer 11. NCT Phase III Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer

13 12. NCT Phase II Study of Samarium Sm 153 Lexidronam Pentasodium and 3- Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Rising Prostate-Specific Antigen Levels after Radical Prostatectomy for Prostate Cancer (KP) 13. NCT Phase II Study of Herbal Therapy for Treatment of Recurrent Prostate Cancer (USC) 14. NCT Phase II Study of Hypo-Fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer (UCLA) 15. NCT Phase II Study of MDV3100 vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer (CS) 16. NCT Phase I/II Study to Test the Safety & Effectiveness of Docetaxel with RAD001 and Bevacizumab in Men with Advanced Prostate Cancer (USC) 17. NCT Phase I/II Study of Adjuvant Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer (USC) 18. NCT Phase I/II Study of Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer (USC) 13 A. Bladder 9. Urologic Cancers (other) 1. NCT Phase III Trial of Gemcitabine after Surgery in Treating Patients with Newly Diagnosed or Recurrent Bladder Cancer (CS, USC) 2. NCT Phase III Efficacy and Safety Evaluation Study of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared with Mitomycin C in the Intravesical Treatment of Subjects with BCG Recurrent/Refractory Non-Muscle Invasive Bladder Cancer (AIR) 3. NCT Phase II Study of Tamoxifen in Treating Patients with Metastatic Bladder Cancer that did not Respond to Previous Chemotherapy (USC) 4. NCT Phase II Trial of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder (USC) B. Kidney Cancer 1. NCT Phase III Study of Everolimus in Treating Patients with Kidney Cancer who have Undergone Surgery (GMH) 2. NCT Phase III Study of TKI258 vs. Sorafenib in Patients with Metastatic Renal Cell Carcinoma (UCLA) 3. NCT Phase III Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (GSK) 4. NCT Phase II Study of Bevacizumab and Interleukin-2 in Treating Patients with Metastatic Kidney Cancer (UCLA) 5. NCT Phase II Trial using Vaccine Therapy in Treating Patients with Newly Diagnosed Stage IV Kidney Cancer (UCLA)

14 6. NCT Phase II Efficacy and Safety Comparison Study of RAD001 vs. Sunitinib in the First-Line and Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma (UCLA) 7. NCT Phase II Trial using Pazopanib Hydrochloride in Treating Patients with Stage IV Kidney Cancer (SPCC) 8. NCT Phase II Study of MK2206 or Everolimus in Treating Patients with Refractory Kidney Cancer (USC) 9. NCT Phase II Biomarker Study of Tivozanib in Subjects with Advanced Renal Cell Carcinoma (UCLA) 10. NCT Phase I/II Study of Bortezomib and Bevacizumab ("BB-mib-mab") in Patients with Advanced or Recurrent Renal Cell Cancer (RCC) (USC) 11. NCT Phase I/II Trial of E7389 in Treating Patients with Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (COH, TCRF, USC) 12. NCT Phase I/II Trial Of CVX-060, an Anti-Angiogenic COVX-Body, in Combination with Sunitinib in Patients with Advanced Renal Cell Carcinoma (PFIZER) 14 Hematologic Cancers 1. Leukemia 1. NCT Phase III Study of Elacytarabine vs. Investigator's Choice in Patients with Late Stage Acute Myeloid Leukaemia (AML) (SCCC, UCLA) 2. NCT Phase III Study of Vosaroxin or Placebo in Combination with Cytarabine in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) (UCLA) 3. NCT Phase II Study of Azacitidine with or without Entinostat in Treating Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (SJMC) 4. NCT Phase II Study of Azacitidine and Gemtuzumab in Treating Older Patients with Previously Untreated Acute Myeloid Leukemia (SJMC) 5. NCT Phase II Study of NRX Therapy for Patients with Relapsed or Refractory Acute Promyelocytic Leukemia (SOC) 6. NCT Phase II Efficacy and Safety Study of Midostaurin in Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia (UCLA) 7. NCT Phase II Open-Label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK in Subjects with Relapsed or Refractory Leukemias (GSK) 8. NCT Phase II Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated with Imatinib when Switched to Nilotinib Treatment (USC) 9. NCT Phase II Study of ABT-263 in Combination with Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients with B-Cell, Chronic Lymphocytic Leukemia (CLL) 10. NCT Phase II Trial Evaluating PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (UCLA) 11. NCT Phase I Study of Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients with Previously Treated Chronic Phase Chronic Myelogenous Leukemia (COH)

15 12. NCT Phase I Study of LY Sodium in Essential Thrombocythemia and Acute Myeloid Leukemia 13. NCT Phase I Study to Investigate CAL-101 in Combination with Chemotherapeutic Agents and CD20 mab in Patients with Relapsed or Refractory Indolent B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (UCLA) 14. NCT Phase I First in Human Study to Determine the Safety, Tolerability and Preliminary Effectiveness of MDX-1338 (BMS ) in Subjects with Acute Myelogenous Leukemia (AML) (UCLA, USC) Lymphoma 1. NCT Phase III Randomized Study of Rituximab and Combination Chemotherapy in Treating Patients with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (GMH, PHS) 2. NCT Phase III Multicenter Selective Lymphadenectomy Trial II (MSLT-II) (SJHC) 3. NCT Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 vs. Matching Placebo after Patients have Achieved Complete Response with First-Line Rituximab-Chemotherapy (USC) 4. NCT Phase III Study Of Inotuzumab Ozogamicin Plus Rituximab for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients who are not Candidates for Intensive High-Dose Chemotherapy (PFIZER) 5. NCT Phase III Comparison Study of Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma who have Relapsed after Therapy and are not Eligible for Stem Cell Transplant (TCRF) 6. NCT Phase II Single Agent Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-Cell Lymphoma (UCLA) 7. NCT Phase II Trial of Homoharringtonine Injections in Treating Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia that did not Respond to Imatinib Mesylate (USC) 8. NCT Phase II Study of Rituximab Plus CHOP Given Every Two Weeks with Sargramostim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (USC) 9. NCT Phase II Study of Vorinostat and Rituximab in Treating Patients with Indolent Non- Hodgkin Lymphoma (COH, TCRF) 10. NCT Phase II Study to Determine the Efficacy and Safety of Lenalidomide in Patients with Mantle Cell NHL who have Relapsed or Progressed after Treatment with Bortezomib or are Refractory to Bortezomib. The "EMERGE" Trial (TCRF) 11. NCT Phase II Study to Assess the Effectiveness of RCHOP with or without VELCADE in Previously Untreated Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Patients (TCRF, UCLA, USC) 12. NCT Phase II Study of PK-Directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients (CS) 13. NCT Phase II Study of Pralatrexate to Treat Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (TCRI) 14. NCT Phase II Study of YM155 Plus Rituximab in Subjects with Non-Hodgkin's Lymphoma who have Received Prior Treatment (TCRI) 15. NCT Phase II Study of RAD001 in Patients with Relapsed/Refractory Hodgkin Lymphoma that has Progressed after High-Dose Chemotherapy and Autologous Stem Cell Transplant and/or after Gemcitabine- or Vinorelbine- or Vinblastine-Based Treatment (UCLA)

16 16. NCT Phase II Safety and Efficacy Study of PLX3397 in Adults with Relapsed or Refractory Hodgkin Lymphoma (UCLA) 17. NCT Phase I/II Trial of Bortezomib, Ifosfamide, Carboplatin, and Etoposide, with or without Rituximab, in Treating Patients with Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma (UCLA, USC) 18. NCT Phase I/II Safety Study of CAT-8015 to Treat Advanced B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) (CS) 19. NCT Phase I/II Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients with Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma (UCLA) 20. NCT Phase I Study of MLN9708 in Adult Patients with Lymphoma (TCRF) 21. NCT Phase I Study of Autologous Vaccine for Follicular Lymphoma 22. NCT Phase I Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules) in Adult Patients with Advanced Solid Tumors (UCLA) 23. NCT Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK & GSK (GSK) 24. NCT Phase I Study of the Safety and Pharmacology of MEGF0444A in Combination with Bevacizumab with or without Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors Myeloma 1. NCT Phase III Trial of Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients with Stage II-III Multiple Myeloma (CS) 2. NCT Phase III Study of Lenalidomide and Dexamethasone with or without Bortezomib in Treating Patients with Previously Untreated Multiple Myeloma (PH, SJMC) 3. NCT Phase III Trial using Panobinostat or Placebo with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (KRI) 4. NCT Phase III Study of Lenalidomide vs. Placebo in Subjects with Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) without Del 5Q (UCLA) 5. NCT Phase III Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs. Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma (SJMC) 6. NCT Phase III Study of Aplidin - Dexamethasone in Relapsed/Refractory Myeloma (UCLA) 7. NCT Phase III Study of Pomalidomide in Persons with Myeloproliferative-Neoplasm- Associated Myelofibrosis and RBC-Transfusion-Dependence (UCLA) 8. NCT Phase II Study to Evaluate Two Lenalidomide Dose Regimens with Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma (VAMC) 9. NCT Phase IB/II Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma (TCRF) 10. NCT Phase I/II Study of Melphalan and Panobinostat in Treating Patients with Recurrent Multiple Myeloma (OT) 11. NCT Phase I/II Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma (UCLA) 12. NCT Phase I/II Study of Carfilzomib for Multiple Myeloma Patients who are Relapsed/Refractory to Bortezomib-Containing Treatments (OT)

17 NCT Phase I Safety Study of LY in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma (UCLA) 14. NCT Phase I Study of Panobinostat and Everolimus in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma (COH) Phase I Studies 1. NCT Phase I Study of Fenretinide in Treating Patients with Refractory or Relapsed Hematologic Cancer (USC) 2. NCT Phase I Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of PF in Patients With Advanced Solid Tumors (PFIZER) 3. NCT Phase I Trial using PXD101 and Isotretinoin in Treating Patients with Solid Tumors that are Metastatic or that cannot be Removed by Surgery (USC) 4. NCT Phase I Study to Assess Long Term Safety Of Pazopanib (GSK) 5. NCT Phase I Trial using Fenretinide in Treating Patients with Metastatic or Unresectable Malignant Solid Tumors (COH, USC) 6. NCT Phase I Study of E7389 and Cisplatin in Treating Patients with Advanced Solid Tumors (COH, USC) 7. NCT Phase I Safety Study of CAT-8015 Immunotoxin in Patients with CLL, PLL or SLL with Advance Disease (TCRF) 8. NCT Phase I Safety Study of CAT-8015 Immunoxin in Patients with NHL with Advance Disease (TCRF) 9. NCT Phase I Study of Veliparib, Carboplatin, and Paclitaxel in Treating Patients with Advanced Solid Cancer (USC) 10. NCT Phase I Trial to Study the Side Effects of Bortezomib and Topotecan Hydrochloride in Treating Patients with Advanced Solid Tumors (COH) 11. NCT Phase I Trial using Dasatinib in Treating Patients with Metastatic or Unresectable Solid Tumor or Lymphoma (USC) 12. NCT Phase I Study of Abraxane Weekly and Three Weekly Schedule with Vandetanib (USC) 13. NCT Phasae I Study of Pazopanib in Treating Patients with Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (COH, USC) 14. NCT Phase I Safety Study of CALAA-01 to Treat Solid Tumor Cancers (COH) 15. NCT Phase I Study of Multiple Ascending Dose (MDX ) (ACRI) 16. NCT Phase I Ascending Multiple-Dose Study of Brivanib Alaninate in Combination with Chemotherapeutic Agents in Subjects with Advanced Cancers (USC) 17. NCT Phase I Study of Lapatinib and Ixabepilone in Treating Patients with Advanced Solid Tumors (USC) 18. NCT Phase I Dose Escalation Study of ARQ 621 in Adult Patients with Metastatic Solid Tumors and Hematologic Malignancies (PO) 19. NCT Phase I Safety Study of PEGPH20 Given to Patients with Advanced Solid Tumors (PO) 20. NCT Phase I Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients with HER2-Positive Metastatic or Locally Advanced Inoperable Cancer 21. NCT Phase I Trial To Assess Safety And Tolerability Of PF in Cancer Patients (PFIZER)